With a market value of $50.3 billion, Becton, Dickinson & Company (BDX) is a global medical technology leader based in Franklin Lakes, New Jersey. It develops, manufactures, and sells a wide range of medical devices, devices, and interventional solutions.
Companies valued at $10 billion or more are typically classified as “large-cap stocks,” and BDX fits the label perfectly, with its market cap exceeding that threshold, indicating its size, influence, and dominance in the medical device and supplies industry. By prioritizing innovation in high-growth areas such as biologic drug delivery, automated medication management, and advanced patient monitoring, the company continues to transform the world of health by improving clinical outcomes and operational efficiency for providers and patients.
The healthcare giant is currently trading $5.8 below its 52-week high of $187.35 reached on February 24. Shares of BDX have risen 15.8% over the past three months, significantly outpacing the Dow Jones Industrial Average ($DOWI)’s 3.3% rise over the same time frame.
Additionally, on a YTD basis, BDX shares are up 15.7% compared to the DOWI’s 1.9% increase. However, over the past 52 weeks, the BDX has risen slightly, lagging behind the DOWI’s 13.3% rise.
Confirming its bullish trend, the BDX has been trading above its 200-day moving average since late November, with little volatility, and has remained above its 50-day moving average since mid-November.
On February 9, BDX shares fell 1.3% despite reporting better-than-expected Q4 results. The company’s revenue rose 1.6% year-over-year to $5.3 billion, beating consensus estimates. However, its management remains cautious about continued macroeconomic and regulatory disruptions, particularly from China and vaccine demand, which may have unsettled investors. Additionally, adjusted EPS of $2.91 handily beat analyst expectations of $2.82.
BDX is particularly competitive with its competitor, Intuitive Surgical, Inc. ( ISRG ), which has fallen 10.7% over the past 52 weeks and is down 11.1% on a YTD basis.
Given BDX’s recent good performance, analysts are moderately optimistic about its prospects. The stock has a consensus rating of “moderate buy” from the 14 analysts that cover it, and an average price target of $194.08 suggests a 10% premium to its current price level.
As of the date of publication, Niharika Jain held no positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article is for informational purposes only. This article was originally published on Barchart.com
(Tags translation) Becton Dickinson
